Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Apr 15;11(4):850.
doi: 10.3390/nu11040850.

Chokeberry Juice Containing Polyphenols Does Not Affect Cholesterol or Blood Pressure but Modifies the Composition of Plasma Phospholipids Fatty Acids in Individuals at Cardiovascular Risk

Affiliations
Randomized Controlled Trial

Chokeberry Juice Containing Polyphenols Does Not Affect Cholesterol or Blood Pressure but Modifies the Composition of Plasma Phospholipids Fatty Acids in Individuals at Cardiovascular Risk

Biljana Pokimica et al. Nutrients. .

Abstract

Chokeberry polyphenols have been suggested to reduce cholesterol and blood pressure and thus protect against cardiovascular diseases (CVD), but the evidence in humans is limited and inconsistent. This randomized double-blinded three-parallel groups trial investigated the changes in various anthropometric and clinical biomarkers, and in plasma phospholipids fatty acids (PPFA) in volunteers at cardiovascular risk after a four-week intervention with 100 mL/day of (1) chokeberry juice with a high-dose of polyphenols (1177.11 mg gallic acid equivalents, GAE); (2) chokeberry juice with a low-dose of polyphenols (294.28 mg GAE) and; (3) a nutritionally matched polyphenol-free placebo drink. Our results indicate that the intake of chokeberry juice containing either the low or the high dose of polyphenols cannot be linked with a reduction in total- and low-density lipoprotein (LDL)cholesterol or in systolic (SBP) and diastolic (DBP) blood pressure in comparison with the consumption of the placebo drink. However, we found evidence of moderate changes in the PPFA, i.e., increased saturated fatty acids (SFA), mostly palmitic acid, and reduced n-6 polyunsaturated fatty acids (PUFA), principally linoleic acid (LA) with the intake of chokeberry against the placebo. These effects may be associated with the polyphenols but we could not differentiate a clear dose-response effect. Further research is still needed to elucidate the contribution of the polyphenolic fraction to the potential cardiovascular effects of the chokeberry and to build up the evidence of its potential benefit via the modulation of PPFA composition.

Keywords: Aronia; SFA; anthocyanins; blood pressure; cardiovascular risk factors; hyperlipidemia; n-6 PUFA; obesity; palmitic acid; polyphenols.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart indicating the number of participants selected and allocated to the different intervention groups and analyses. FSG: fasting serum glucose; TAGs: triglycerides; T-C: total-cholesterol; HDL-C: High-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; oxLDL: oxidized low-density lipoprotein; PPFA: plasma phospholipids fatty acids; PLB: placebo; AMJd: polyphenol low-dose chokeberry juice; AMJ: polyphenol high-dose chokeberry juice.

Similar articles

Cited by

References

    1. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corrà U., Cosyns B., Deaton C., et al. European Guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Atherosclerosis. 2016;252:207–274. - PubMed
    1. Stewart J., Manmathan G., Wilkinson P. Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM Cardiovasc. Dis. 2017;6 doi: 10.1177/2048004016687211. - DOI - PMC - PubMed
    1. Huang H., Ma R., Liu D., Liu C., Ma Y., Mai W., Dong Y. Oxidized low-density lipoprotein cholesterol and the ratio in the diagnosis and evaluation of therapeutic effect in patients with coronary artery disease. Dis. Mark. 2012;33:295–302. doi: 10.1155/2012/167143. - DOI - PMC - PubMed
    1. Burgos Alves M.I., Avilés Plaza F., Martínez-Tomás R., Sánchez-Campillo M., Larqué E., Pérez-Llamas F., Martínez Hernández P., Parra Pallarés S. Oxidized LDL and its correlation with lipid profile and oxidative stress biomarkers in young healthy Spanish subjects. J. Physiol. Biochem. 2010;66:221–227. doi: 10.1007/s13105-010-0028-4. - DOI - PubMed
    1. Clarke R., Shipley M., Armitage J., Collins R., Harris W. Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servants. Br. J. Nutr. 2009;102:279–284. doi: 10.1017/S0007114508143562. - DOI - PubMed

Publication types

MeSH terms